中国实用妇科与产科杂志2023，Vol.39Issue(12)：1225-1232,8.DOI:10.19538/j.fk2023120116
2023年中国卵巢癌诊疗现状白皮书
White paper on the current state of ovarian cancer diagnosis and treatment in China in 2023
李璡 1温灏 1刘淑娟 2邹冬玲 3李俊东 4王静 5朱笕青 6孙力 7吴小华1
作者信息
- 1. 复旦大学附属肿瘤医院妇科复旦大学上海医学院肿瘤学系,上海 200032
- 2. 空军军医大学西京医院妇产科,陕西西安 710032
- 3. 重庆大学附属肿瘤医院妇瘤科,重庆 400030
- 4. 中山大学肿瘤防治中心妇科,广东广州 510060
- 5. 湖南省肿瘤医院妇瘤科,湖南长沙 410013
- 6. 中国科学院大学附属肿瘤医院妇瘤科,浙江杭州 310022
- 7. 中国医学科学院肿瘤医院深圳医院妇科,广东深圳 518117
- 折叠
摘要
Abstract
Objective To investigate the current clinical diagnosis and treatment status of ovarian cancer in China,identify unmet needs among healthcare professionals and patients,and further standardize the level of ovarian cancer diagnosis and treatment in China.Methods In 2023,a nationwide survey was conducted,involving 571 doctors and 1270 patients from 30 provinces in China.The survey questionnaire primarily covered patient pathology types,treatment modalities,genetic testing,surgical procedures,maintenance therapy,and medication preferences.Results A total of 427 doctors and 1158 patients completed the survey.A comparative analysis between the 2022 and 2023 survey questionnaires revealed that after initial treatment,97％of patients received adjuvant chemotherapy,representing a 4％increase from 2022.Moreover,96％of doctors rec-ommended BRCA1/2 testing to guide treatment,with 75％of patients undergoing BRCA gene testing,marking a 4％increase from 2022.With the increased availability of medications and recognition of their efficacy,there has been a gradual rise in patient's demand for maintenance therapy.The proportion of patients in the surveyed population who were actively undergoing maintenance therapy was 63％,repre-senting a 10％growth from 2022.Among patients not initially advised by doctors to unergo maintenance therapy,52％ex-pressed a willingness to receive this treatment.If BRCA-patients achieved a median progression-free survival(PFS)of 12 months,76％of doctors considered maintenance therapy necessary,and if BRCA-/HRD-patients achieved a median PFS of 9 months,73％of doctors believed maintenance therapy to be essential,indicating that the effectiveness of mainte-nance therapy was gradually gaining recognition among physicians in the treatment of BRCA-patients.Conclusion The findings of this research reflect the current state of ovarian cancer diagnosis and treatment in China.The study primarily focuses on aspects such as BRCA 1/2 genetic testing among ovarian cancer patients,their primary treatment modalities,and physicians'recommendations and patient choices regarding maintenance therapy.These insights provide valuable ref-erences for the standardization of ovarian cancer diagnosis and treatment in China.关键词
卵巢癌/诊断/治疗/维持治疗/白皮书Key words
ovarian cancer/diagnosis/treatment/maintenance therapy/white paper分类
医药卫生引用本文复制引用
李璡,温灏,刘淑娟,邹冬玲,李俊东,王静,朱笕青,孙力,吴小华..2023年中国卵巢癌诊疗现状白皮书[J].中国实用妇科与产科杂志,2023,39(12):1225-1232,8.
